Eli Lilly And Co (NYSE:LLY) had its price target increased by analysts at Mizuho from $155.00 to $164.00 in a research note issued on Monday, The Fly reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential downside of 0.11% from the company’s previous close.
A number of other brokerages also recently weighed in on LLY. Bank of America reaffirmed a “buy” rating and set a $180.00 price target on shares of Eli Lilly And Co in a report on Friday, June 19th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price target for the company in a report on Wednesday, March 11th. Guggenheim raised shares of Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price target for the company in a report on Tuesday, June 16th. Cowen upped their price target on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Finally, Morgan Stanley cut shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research report on Sunday, April 19th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $168.58.
NYSE LLY opened at $164.18 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37. The company has a market capitalization of $155.63 billion, a P/E ratio of 27.14, a P/E/G ratio of 1.51 and a beta of 0.24. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $167.43. The firm has a 50-day moving average price of $154.33 and a two-hundred day moving average price of $143.38.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The company had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same quarter in the prior year, the firm posted $1.33 EPS. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. Equities analysts expect that Eli Lilly And Co will post 6.82 EPS for the current year.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 166,038 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $140.78, for a total value of $23,374,829.64. Following the completion of the transaction, the insider now directly owns 113,155,330 shares in the company, valued at approximately $15,930,007,357.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Aarti S. Shah sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the transaction, the senior vice president now owns 19,087 shares of the company’s stock, valued at $2,863,050. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 982,938 shares of company stock valued at $151,390,042. Corporate insiders own 0.09% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Pacitti Group Inc. acquired a new position in Eli Lilly And Co in the 4th quarter valued at approximately $25,000. Stonebridge Financial Planning Group LLC boosted its stake in shares of Eli Lilly And Co by 70.0% in the 1st quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Truvestments Capital LLC bought a new stake in shares of Eli Lilly And Co in the 1st quarter valued at $27,000. Solstein Capital LLC bought a new stake in shares of Eli Lilly And Co in the 4th quarter valued at $34,000. Finally, Capital Wealth Alliance LLC bought a new stake in shares of Eli Lilly And Co in the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 77.44% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Earnings Reports
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.